Induced pluripotent stem cells (iPS cells), generated by transcription factor-dependent nuclear reprogramming of differentiated somatic cells, are pluripotent stem cell lines that can be propagated indefinitely in culture and maintain the potential to differentiate into any cell type in the body. As iPS cells retain the same genetic make-up as the somatic cell targeted for reprogramming, these cells hold tremendous promise for uncovering novel genetic and biochemical factors that underlie diseases with complex and poorly understood genetic influences, such as diabetes. The newly established iPS Core maintains a centralized facility for the reliable and consistent generation and propagation of reprogrammed iPS cells for use in cutting-edge research into the molecular and cellular pathologies underlying diabetes and its complications.
Experimental design and IRB documentation. New and existing DRC investigators who wish to employ iPS cells in their experiments should begin by contacting the iPS Core for consultation. An initial meeting will be scheduled involving the Core Director, Associate Directors, the Core’s Clinical Research Nurse and the investigator, in which the aims, experimental design, approach, and requirements for human subjects research are discussed.
2. Patients. Assistance in identifying patients who fit study criteria for the specific aims of the investigators using the Core from among Joslin’s patient population and through local advertising (flyers in Joslin public areas, web-postings, etc.) using IRB-approved postings.
3. Patient Samples. Skin punch biopsies, peripheral blood, or other pertinent tissue will be obtained under informed consent for reprogramming studies. Punch biopsy and/or venapuncture will be performed in Joslin’s Clinical laboratory (located on the 3rd floor of the Joslin Diabetes Center), by trained medical staff.
4. Sample cell culture, expansion and storage. Fibroblasts from human skin biopsies and mononuclear cells from peripheral blood are expanded under standard conditions. All samples collected and expanded will be cryopreserved and banked at Joslin.
5. Non-integrative Reprogramming. Human iPSC lines will be generated from cultured fibroblasts, peripheral blood, or other relevant cell types using Sendai virus or episomal plasmid transfection.
6. Validation and quality control of iPS lines. Our core services include pluripotency characterization (including Flow Cytometry, Real-Time PCR, and Teratoma Formation analysis), Karyotyping, and Mycoplasma testing.
7. iPS cell line expansion, banking, and distribution.
8. Isolation of DNA, RNA or protein purified from iPS lines.
9. Discounted iPS culture reagents. Joslin users can purchase discounted iPS culture reagents from a variety of vendors directly through Joslin's
10. Training in iPS cell culture and subsequent use of core facilities for self run studies. Workshops for iPS culture training are scheduled bi-annually. For information on protocols and techniques used by the core, please visit the
11. Genome Editing Services. Our core has recently been able to provide genome modification services using the CRISPR/Cas9 system in iPSC and other cell lines. Investigators should contact core personnel to set up a meeting to discuss details of their project.
The Joslin iPS core is a member of the
COREdinates stem cell consortium, a group of stem cell cores working to standardize human pluripotent stem cell practices to facilitate research.
For questions about the iPS Core and its services, please contact Amy Wagers:
Amy.Wagers@joslin.harvard.edu or email:iPSCore@joslin.harvard.edu.